TLDR:
Several hedge fund firms specializing in life sciences and biopharma investments are exceeding their deal-making pace from previous years in the venture capital market, with separate VC funds in addition to their hedge funds. RA Capital Management, Perceptive Advisors, Cormorant Asset Management, and RTW Investments are among those making significant investments in various biotech companies, with recent participation in PIPE financings of Bicycle Therapeutics and CARGO Therapeutics.
Several life sciences and biopharma hedge funds are on pace to do more deals than in the last three years.
RA Capital Management remains the most active biopharma hedge fund firm in the VC market, making 46 deals in the first half of the year.
Perceptive Advisors made 31 private investments in the first half of the year, exceeding their previous yearly totals.
Other biopharma funds, like Cormorant Asset Management and RTW Investments, are also on track to exceed their deal-making pace from prior years.
Hedge fund firms recently participated in PIPE financings of Bicycle Therapeutics and CARGO Therapeutics.
